This test requires professional lab infrastructure and staff. This test cannot be performed by private individuals and we do not sell the kits to such individuals. If you suspect you are infected with SARS-CoV-2, please contact your healthcare provider.
The COVID19-REAAD™ Anti- SARS-CoV-2 lgG ELISA kit is a valuable assay for the detection of IgG antibodies against SARS-CoV-2 nucleocapsid protein antigen. This kit provides qualitative and semi-quantitative data for the identification of immune responses to SARS-CoV-2 infection. It can be used to determine recent or prior exposure to SARS-CoV-2 and is useful for the research of SARS-CoV-2 immune responses and serological population surveys.
Ready to use Microplate coated with recombinant SARS-CoV-2 Nucleocapsid protein, 12 strips x 8 microwells
20X Wash Buffer Concentrate
100X Positive Control
100X Negative Control
100X Reference Control
Ready to use Diluent
100X Anti-IgG HRP Conjugate
Ready to use TMB Substrate Solution
Ready to use Stop Solution
Resealable Bag for unused microwells
Instructions for use
The amount of reagents is sufficient for 5 optimal runs.
Antigen: Recombinant SARS-CoV-2 N protein
Sample type: Serum, Plasma
For the assay to be valid:
- The reagent Blank control absorbance should be ≤ 0.200.
- The Negative Control absorbance should be ≤ 0.300.
- The Reference Control absorbance should be between 0.500 and 0.800.
- The Positive Control absorbance should be ≥ 1.200.
The index could be calculated as follows:
ODsample – ODblank
——————————- X1 = Index
ODReference – ODblank
Interpretation of Data:
Negative: Index < 1
Borderline: 1.1 > Index ≥ 0.9
Positive: Index > 1
In case of a borderline results, a secure evaluation is not possible. It is recommended the samples should be repeat tested in duplicate. If one or more results are positive the final interpretation of the specimen is positive; if the repeat results are borderline or negative the final interpretation is borderline and another specimen should be collected.